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Abstract
Background: A Target Product Profile (TPP) outlines the necessary characteristics of an innovative product to
address an unmet clinical need. TPPs could be used to better guide manufacturers in the development of ‘fit for
purpose’ tests, thus increasing the likelihood that novel tests will progress from bench to bedside. However, there is
currently no guidance on how to produce a TPP specifically for medical tests.
Methods: A systematic review was conducted to summarise the methods currently used to develop TPPs for
medical tests, the sources used to inform these recommendations and the test characteristics for which targets are
made. Database and website searches were conducted in November 2018. TPPs written in English for any medical
test were included. Based on an existing framework, test characteristics were clustered into commonly recognised
themes.
Results: Forty-four TPPs were identified, all of which focused on diagnostic tests for infectious diseases. Three core
decision-making phases for developing TPPs were identified: scoping, drafting and consensus-building.
Consultations with experts and the literature mostly informed the scoping and drafting of TPPs. All TPPs provided
information on unmet clinical need and desirable analytical performance, and the majority specified clinical validity
characteristics. Few TPPs described specifications for clinical utility, and none included cost-effectiveness.
Conclusions: We have identified a commonly used framework that could be beneficial for anyone interested in
drafting a TPP for a medical test. Currently, key outcomes such as utility and cost-effectiveness are largely
overlooked within TPPs though and we foresee this as an area for further improvement.
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Background
Despite significant advances and innovation in the field
of disease detection, the majority of the resulting tech-
nologies fail to be translated into tests that are used in
clinical practice [1, 2]. For instance, it is estimated that
less than 1% of novel cancer biomarkers actually reach
clinical practice [3]. One possible driver is that the
development of new tests is often driven by laboratory
discoveries rather than by clinical needs [4]. Test manu-
facturers have to fulfil extensive evidence requirements
demonstrating the fitness of their test for clinical prac-
tice [5]. A poor understanding of unmet clinical needs
and the clinical pathway, within which a test will sit, will
often mean that the clinical and economic benefits can-
not be convincingly demonstrated and hence the test
may fail to be adopted into clinical practice [1].
Under the ‘Quality by design’ framework, a new prod-
uct is designed with the aim of meeting pre-identified
quality objectives [6]. A Target Product Profile (TPP),
also known as a Quality Target Product Profile (QTPP),
is a strategic document which summarises the necessary
characteristics of an innovative product to address an
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unmet clinical need [7]. TPPs exemplify the concept of
‘beginning with the goal in mind’, establishing key fea-
tures and performance specifications in advance to en-
sure that the new product is developed to meet specific
health-related goals [7, 8]. TPPs should also be seen as
‘living’ documents that can be refined and updated as
additional relevant information becomes available [7, 9].
TPPs could therefore be particularly useful when de-
signing ‘fit for purpose’ medical tests [10]; they could be
used during the development and manufacturing phase
to ensure that a new test meets pre-established oper-
ational and performance requirements, in line with un-
met clinical need [7]. Generating the required evidence
for a new test can take many years and significant in-
vestment [11]. TPPs therefore have great potential to be
used as guiding documents for test developers to avoid
late-stage development failures and reduce research
waste.
Although we are aware of some examples where TPPs
have been developed for medical tests, to our knowledge,
there is no formal guidance as to best practice methods.
In the USA, guidance for developing TPPs is available
for new pharmaceutical drugs [7]. This guidance, issued
by the US Food and Drug Administration (FDA), pro-
vides an overview of the purpose and attributes of TPPs,
and which requirements for a new drug should be in-
cluded [7]. In this context, TPPs are used as voluntary
briefing documents to stimulate discussion between the
manufacturer and the FDA throughout the drug devel-
opment process [7]. The TPP itself outlines specific cri-
teria that a new drug should meet [7]. However, medical
tests differ from pharmaceuticals, both in terms of their
characteristics and in the indirect way in which they im-
pact on patient health [5], and therefore, this guidance is
not directly transferable to the context of medical tests.
Here we report a systematic review of the methods
currently used to develop TPPs for medical tests, allow-
ing us to (1) describe a commonly adopted methodology
framework, (2) outline the test characteristics for which
targets are often set and (3) identify areas requiring fur-
ther methodological development.
Methods
The protocol for this review was registered on the
PROSPERO database (CRD42018115133) [12].
Search strategy
Details of the full search strategy can be found in
Additional file 1. The following electronic databases
were searched: MEDLINE, EMBASE, CAB Abstract
Online, CINHAL, Global Health, Scopus and Web of
Science. The database search was performed in No-
vember 2018 and encompassed a combination of key
terms such as ‘TPP’, ‘quality by design’, ‘QTPP’ and
‘test’.
The grey literature and websites were also searched
using structured methods proposed by Godin et al. [13]. A
customised Google search was conducted to identify rele-
vant websites, and then, each of these websites was hand-
searched. For each website, the internal search engine was
used supplemented with hand-searching to identify poten-
tially relevant references. Duplicates across searches were
removed. This search was also conducted in November
2018. For more details, please see Additional file 1:
Table 1.3, Table 1.4 and 1.5.
All searches were conducted by PC and peer reviewed
by an information specialist.
Screening
TPPs written in English for any type of medical test were
included (e.g. imaging, in vitro and in vivo medical
tests). There were no restrictions in terms of publication
date. All publication formats were included except for
newsletters and PowerPoint presentations, as these did
not report the methods in sufficient detail to review
them.
Endnote was used to manage references. Titles and ab-
stracts of the retrieved references were fully screened by
PC based on the inclusion criteria, of which a random
10% sample was independently screened by BS. TPPs
that met the inclusion criteria at this stage or those for
which it was not possible to determine eligibility based
on title and abstract were then screened based on the
full text. For those references where full text was not
available, we contacted authors. All full texts of the eli-
gible TPPs at this stage were screened independently by
PC and BS based on the inclusion criteria. The inter-
reviewer agreement rate was calculated with Cohen’s κ
statistic. For more details, please see Additional file 3:
Table 3.1 and 3.2. Where any disagreements occurred, a
consensus-based discussion with the other authors
(MM, RW) determined whether the reference was eli-
gible or not.
Data extraction and analysis
A data extraction spreadsheet was developed including
basic descriptive information relating to the TPP (e.g.
publication format, disease of interest, targeted clinical
setting, funder, time horizon). Further to this, we ex-
tracted data on the methodology used to develop the
TPP, including details of the input sources (e.g. expert
consultation, review of the literature), the reported
decision-making process and the stakeholders involved
at each stage of the TPP development. As a common
decision-making framework was apparent across the
TPPs, we summarised the input sources and stake-
holders involved for each phase of this process. Where
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stakeholders and input sources for the drafting phase
were not explicitly reported for, we assessed the sources
included in each TPP table and the longer descriptions
of each test characteristic.
Each TPP was also assessed in terms of the transpar-
ency of reporting the adopted input sources, decision-
making process and which stakeholder groups were
consulted.
All data extraction was conducted independently by
PC and AAS, and in case of disagreement, BS, MM and
RW resolved any differences.
Test characteristic clustering
In addition to the information above, the test character-
istics reported within each TPP were extracted and de-
duplicated. Based on an existing evaluation framework
for tests (the ACCE framework [14]), two reviewers (BS
and MM) independently categorised each of the test
characteristics under the following outcomes: (1) test
definition, (2) analytical performance, (3) clinical validity,
(4) clinical utility, (5) regulatory legitimacy and (6) eco-
nomic acceptability. The category ‘test definition’ speci-
fies the disorder of interest, target population and
purpose of the test, and thus, it overlaps with the con-
cept of ‘unmet clinical need’. Therefore, we renamed the
outcome ‘test definition’ as ‘unmet clinical need’ to bet-
ter represent the type of information TPPs provide.
Analytical performance describes the ability of a test
to correctly detect and measure a particular analyte (e.g.
precision, trueness, analytical sensitivity and specificity,
limits of detection) [15, 16]. Clinical validity is defined as
‘the ability of a device to yield results that are correlated
with a particular clinical condition or a physiological or
pathological process or state’ [15], whilst clinical utility
represents the ability of a test to affect relevant health-
related outcomes for patients (e.g. improvement in qual-
ity of life, longer lifespan) [17].
Some characteristics did not fall within any of the pre-
defined categories. Three additional categories were
therefore identified to accommodate these additional
characteristics: (7) human factors, (8) environmental im-
pact and (9) infrastructural requirements. Human factors
are concerned with the interaction between users and
devices [18]. Environmental impact encompasses a
change to the environment following an interaction with
the product [19]. Infrastructural requirements entail ‘the
Fig. 1 PRISMA flow diagram illustrating literature search results
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stock of the basic facilities and equipment needed for
realizing a product or providing a service’ [20].
Results
Literature search
Full details of the literature search results are reported
in Fig. 1. Forty-four TPPs were deemed eligible for
inclusion in the systematic review [8–10, 21–61]. Inter-
reviewer agreement was high at title and abstract (κ =
96%) and full-text screening (κ = 98%). For more details,
please see Additional file 3: Table 3.1 and 3.2.
Features of included TPPs
The included 44 TPPs consisted of 23 reports, 16 journal
articles, 4 published TPP tables (a TPP without any
background information or context e.g. [34]) and one
conference poster. All TPPs provided guidance on devel-
oping medical tests to detect infectious diseases. Four-
teen of the 44 TPPs focused on neglected tropical
diseases (32%) (e.g. soil-transmitted helminths, Chagas
disease, human African trypanosomiasis, schistosomiasis,
trachoma, taeniasis cysticercisosis) and on tests for
vector-borne infections (32%) (e.g. Zika virus, dengue
fever, hepatitis C, malaria, E. coli). Other types of
infection included sexually transmitted infections (16%,
n = 7), respiratory infections (14%, n = 6) (e.g. lower re-
spiratory tract infection, tuberculosis, pneumonia), Ebola
virus [57], meningitis [61] and severe febrile illness [8].
Seven of the 44 TPPs were funded by Bill and Melinda
Gates Foundation (16%), and three TPPs received fund-
ing from WHO [8, 48, 49]. The healthcare setting of
interest was mostly low- and middle-income countries.
The majority of TPPs did not disclose funding sources
(64%, n = 28).
In some TPPs, a time horizon was chosen to represent
the timeframe within which achieving the specifications
described in the TPP was considered feasible [22, 23, 60].
In one TPP, this was based on a landscape analysis [22].
In another, expected advancements in technologies and
knowledge related to a certain field seemed to justify the
time horizon considered for the TPP [27]. Of the 44 TPPs
identified, 7 reported the time horizon during which the
information included in the TPP will be relevant for man-
ufacturers (16%). Of these, 6 TPPs stated a time horizon
Fig. 2 Typical activities involved, input sources and stakeholders invited for each decision-making phase
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of 5 years [22, 23, 27, 28, 51, 60], whilst the remaining
considered a time horizon of 10 years [29].
Decision-making steps
A common decision-making framework, consisting of
three distinct phases, was apparent across the included
TPPs: scoping, drafting and consensus-building. Figure 2
presents the most commonly adopted activities, input
sources and engaged stakeholder groups.
Table 1 provides a summary of the stakeholders con-
tributing to each phase. Some of the included TPPs are
not included in Table 1 as they did not report any infor-
mation related to input sources or stakeholder groups
[33–36, 52, 53, 55, 61]. A summary of the input sources
reported to have been used at scoping and drafting
phase can be found in Additional file 3: Table 3.3.
We will therefore describe the aim of each phase and
breakdown the methodology (activities, input sources
and stakeholders) used within the included TPPs where
reported. For specific details on each included TPP, see
Additional file 3: Table 3.4.
Scoping phase methodology
Half of the TPPs provided some information on the
scoping phase (n = 22). The aim of this phase was to
provide an overview of the disease area and the limita-
tions associated with existing technologies. The clinical
problems and unmet needs were defined, in addition to
identification of which test characteristics to include in
the TPP.
Some of the key activities undertaken during the scop-
ing phase included reviewing published literature (n = 6)
or available data (n = 1), and introductory meetings with
stakeholders (n = 4).
Some authors reported (n = 4) [22, 26, 37, 50] that
they had conducted a ‘landscape analysis’, providing in-
formation on the disease area of interest, available diag-
nostic technologies and related characteristics and
limitations. These were usually based on interviews with
stakeholders and reviews of the literature. Only Toskin
et al. [50] conducted a systematic literature review,
reporting the databases searched and key words used.
Consultation with experts (68%, n = 15) and the litera-
ture (36%, n = 8) were the most commonly sought
Table 1 Stakeholders contributing to each phase
Stakeholder groups contributing to each phasea Scoping Drafting Consensus-building
n (%) n (%) n (%)
Researchers 14 (32) 15 (34) 14 (32)
Industry representatives 11 (25) 11 (25) 14 (32)
International public organisations 9 (20) 12 (27) 12 (27)
Clinicians 7 (16) 8 (18) 8 (18)
Representatives of countries and national disease programs 5 (11) 4 (9) 8 (18)
Policy makers 4 (9) 5 (11) 4 (9)
Laboratory experts 3 (7) 5 (11) 3 (7)
Technical/funding agencies 2 (5) 3 (7) 4 (9)
Microbiologists 2 (5) 4 (9) 2 (5)
Implementers 2 (5) 2 (5) 5 (11)
Patient advocates 2 (5) 1 (2) 3 (7)
Non-profit sector 1 (2) 2 (5) 4 (9)
Modellers 1 (2) 1 (2) 1 (2)
Health economists 0 (0) 2 (5) 2 (5)
Donors 2 (5) 3 (7) 1 (2)
Market experts 2(5) 1 (2) 1 (2)
Program manager 1 (2) 2 (5) 2 (5)
Scientific associations 1 (2) 3 (7) 2 (5)
Strategists 1 (2) 1 (2) 0 (0)
Expert (unspecific) 1 (2) 3 (7) 3 (7)
Others 2 (5) 2 (5) 1 (2)
The percentages in relation to stakeholder groups do not add up to 100% because more than one stakeholder group usually contributes to the development of
a TPP
aPercentages are calculated in relation to the total number of included TPPs (n = 44)
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sources of information during the scoping phase (see
Additional file 3: Table 3.3. for a full breakdown). Only
one type of source was considered in 15 TPPs (of which
11 was consulting experts), whilst 7 TPPs considered
more than one source.
Denkinger et al. [22] mapped the diagnostic ecosystem
of interest and then performed a survey to gauge stake-
holders’ preferences. Reipold et al. [48] identified the
main characteristic categories (e.g. scope, performance,
operational characteristics and pricing) to be included in
the TPP.
Five TPPs involved a priority-setting exercise which entailed
ranking each identified health need [23, 28, 32, 48, 60].
During the scoping phase, a variety of stakeholders
were engaged (Table 1).
Drafting phase methodology
The first draft of each TPP was usually prepared by ei-
ther an established working group comprising experts
from different organisations [9, 26, 29, 32, 40, 50, 58] or
authors of the published TPP. There were two cases
where the TPP was drafted by a completely different or-
ganisation [51, 57]. The TPP was often revised several
times, and in some cases, it was then shortened to en-
sure it could be easily communicated to different stake-
holders [22, 23, 28, 29, 60].
Of the 44 included TPPs, 33 of them reported which
input sources were considered during the drafting phase
(75%) (Additional file 3: Table 3.3). Common input
sources for populating test characteristics were expert
consultations (n = 22) and reviews of the literature (n =
22). Some also referred to mathematical models (n = 9),
available data (n = 7), guidelines (n = 6) and ‘field obser-
vations’ (n = 5). Only one TPP was informed by pooled
data from a systematic review [50].
Twenty-six of the 44 TPPs took into consideration more
than one type of source at the drafting phase, as opposed
to 7 TPPs which only adopted one (Additional file 3:
Table 3.3). Meeting inputs were the most common single
source (43%, n = 3).
The stakeholders engaged in the drafting phase are re-
ported in Table 1.
Consensus-building phase methodology
Initial agreement with the TPP was often obtained using
a survey of the stakeholders (n = 14). The survey either
included general questions regarding stakeholders views
on the TPP (n = 4) [22, 25, 27, 51] or adopted a Delphi-
like approach to provide an initial consensus on various
aspects of the TPP (n = 10). A consensus meeting with
stakeholders and experts was typically held (n = 11) and
a revised TPP generally agreed upon. In some cases, an
additional survey was sent to stakeholders on trade-offs
between test attributes [48], or on rating key parameters
[51, 53]. For 2 TPPs, the final TPP draft was presented
to a broader stakeholder base to validate it.
The number of participants invited to the consensus-
building meetings varied (< 20 participants: n = 5; between
20 and 50 participants: n = 7). One meeting included 100
participants [27]. For a few of the TPPs, the authors also
took part in the consensus meetings [29, 38, 58, 60].
Less than half of the included TPPs reported information
on the activities and stakeholders invited to the consensus-
building phase (n = 19). The stakeholders engaged in the
consensus-building phase are reported in Table 1.
Transparency in reporting methods
We also assessed the transparency of the TPPs in terms
of reporting their methodology (see Additional file 3:
Table 3.5). The decision-making process behind the TPP
was not reported in over a quarter of the included TPPs
(n = 16). Further to this, many failed to report which in-
formation sources were considered to populate the TPP
(n = 11). Just under half did not report which stake-
holders were involved in the development of the TPP
(n = 20). Specifically, the name of the organisations
stakeholders were part was only reported in 11 TPPs,
whilst 9 TPPs mentioned personal details of each stake-
holder (20%) and 4 TPPs explained why certain stake-
holders were invited [26, 38, 46, 58]. Sixteen TPPs
reported the source of funding (36%).
There were some TPPs where the methodology was
very clearly reported [26, 28, 38, 60].
Test characteristics included in TPPs
After removing duplicates, 140 different test characteris-
tics were reported across the included TPPs. Some fea-
tures which did not represent test characteristics have
been excluded, such as factors relating specifically to the
disease in question rather than the test. For more infor-
mation, please see Test Characteristics Overview Excel
spreadsheet (Availability of data and materials). Figure 3
shows the test characteristics most frequently reported
(a full list is available in Additional file 2: Table 2.1).
Figure 4 depicts which characteristic categories were
reported in the included TPPs. Details on unmet clinical
need, analytical performance and clinical validity ap-
peared to be consistently reported; however, regula-
tory requirements, environmental footprint and clinical
utility were less frequently considered.
Discussion
We report a systematic review of the methods currently
used to develop Target Product Profiles for medical
tests. Despite TPPs for any medical test being searched,
all of the identified TPPs were focused on diagnostic
tests for infection.
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Fig. 3 Test characteristics frequently reported in all TPPs (n = 44) sorted by categories
Fig. 4 Test characteristic categories in absolute number (n) of included TPPs
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There was generally a lack of transparency and
consistency in reporting the methods underlying TPPs.
This would make it difficult to appraise the recommen-
dations within the TPPs, ascertain whether the recom-
mendations are generalizable to other settings, and
challenging to reproduce.
Relevancy of TPPs for test manufacturers
The purpose of a TPP is to identify, upfront, the essen-
tial characteristics of a test for it to fulfil a pre-
specified, unmet clinical need. This should, in turn, in-
crease the likelihood that the test will be adopted into
clinical practice and reimbursed [1]. A TPP should also
account for contextual aspects that might affect the
test’s real-world performance [10], defining infrastruc-
tural and technical constraints that impact on the im-
plementation into clinical practice. This review shows
that TPPs to date have primarily been developed for
global health applications, as the main funding organi-
sations are WHO, UNICEF and Bill and Melinda Gates
Foundation. The primary focus on infectious diseases
may be explained by the remit of the global organisa-
tions who fund TPPs. WHO included HIV/AIDS,
neglected tropical diseases, tuberculosis and malaria as
priority diseases [62]. Further to this, WHO established
the ‘R&D Blueprint’, which aims to promote R&D activ-
ities (tests, vaccines, medicines) during epidemics [63].
After having identified pathogen to target first, TPPs
are usually commissioned to guide the development
process of new healthcare products which will address
the high-priority pathogen [63].
However, the development of TPPs should not be limited
to one specific disease area or clinical setting; the concept of
‘beginning with an end in mind’ embodied by TPPs could
support both international and national health decision-
makers. This activity should, in turn, stimulate innovation of
new tests driven by clinical needs rather than solely by la-
boratory discoveries. It would also provide manufacturers
with greater clarity around test requirements and confidence
in the market for developing innovative tests.
Identified limitations in current TPP methodology
In reviewing current methodology for developing TPPs
for medical tests, we have identified three key areas
where current TPP methodology could be improved: (1)
oversight of clinical utility, (2) a focus on price rather
than cost-effectiveness and (3) subjectivity of informa-
tion sources. Here we discuss each limitation and the
implications.
Oversight of clinical utility
Very few of the TPPs reported desirable characteristics
relating to the clinical utility of the test. This is not sur-
prising given that the majority of research efforts has
focused on generating evidence on the analytical per-
formance and diagnostic accuracy of a new test [11]. A
highly accurate test does not necessarily mean that the
test will improve patient health, as factors relating to
decision-making and the effectiveness of patient man-
agement strategies could fall short [64].
Assessing the clinical utility of a new test is ex-
tremely challenging. Measuring the impact of a test
on patient health outcomes is difficult as tests tend to
guide patient management decisions, rather than dir-
ectly impacting on patient health outcomes [5].
Therefore, estimating the clinical utility of a test re-
quires evidence of how the information from a test is
incorporated into decision-making and the down-
stream effectiveness of those decisions [65]. In the
case of a new test, this is particularly complicated
given the uncertainty around the mechanisms by
which the test will impact on patient outcomes [65].
Focus on price rather than cost-effectiveness
Although the minimum and optimal price of the tests
featured in many of the TPPs, none of these was driven
by the trade-off between the overall cost implications of
implementing the test and the associated patient bene-
fits. Cost-effectiveness analysis provides a framework to
compare costs and benefits of an intervention against
relevant comparators, including current practice. Spe-
cifically, cost-effectiveness analysis defines whether the
intervention being evaluated represents good value for
money.
It is important to consider the cost of the new test in
the context of the benefits that the test may provide. For
example, a new test may be relatively expensive but may
also improve patient health to the extent that the add-
itional is justified. Conversely, a new test may be rela-
tively cheap but offer no improvements in patient health
and therefore even the marginal increase in cost is not
justified.
Conducting cost-effectiveness analysis at early R&D
stages of new tests can therefore help manufacturers to
avoid significant investments in tests that do not have
the potential to be cost-effective [65].
These first two limitations are particularly relevant
since decision-makers increasingly demand evidence
that a new test improves patient health and is cost-
effective rather than solely evidence of its analytical
and clinical validity [5]. Specifically, many Health
Technology Assessment bodies in Europe, Australia
and North America consider clinical utility, cost and
cost-effectiveness in relation to the target population,
in addition to analytical performance and clinical
validity when assessing new molecular diagnostic
tests [66].
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Subjectivity of input sources
Expert judgement and evidence identified in published
literature were the main sources of information for de-
fining desirable characteristics. Systematic reviews of the
literature, where database searches are reproducible and
the quality of relevant studies are appraised, were not
conducted to identify relevant evidence at the scoping
and drafting phase. This is likely to introduce bias and
subjectivity in terms of the evidence used to underpin
test characteristic recommendations.
Although expert judgement is undoubtedly useful,
relying solely upon this information source has some
limitations, particularly for quantitative estimates. How
humans make probability judgements is highly affected
by many heuristics and systematic biases (e.g. anchoring,
availability, overconfidence and insight bias) [67]. Specif-
ically, previous literature has found a poor understand-
ing of test accuracy among healthcare professionals [68]
as sensitivity and specificity are often misinterpreted and
mistaken for predictive values [68].
Additionally, the quality of expert elicitation heavily
relies on expert selection as it is important to choose ex-
perts with good subject knowledge. Only 4 TPPs de-
scribed how the selection process took place, and
therefore, the quality of expert judgements might be
questioned. Furthermore, many TPPs reported literature
as a source for informing TPPs; however, less than half
of the TPPs cited the references considered. This lack of
transparency might hinder the quality and credibility of
sources on which TPPs are based.
Study limitations
Since this study is a systematic review of publicly avail-
able literature, a key study limitation is that we have in-
evitably missed any confidential or unpublished TPPs
developed in-house by test manufacturers. Although the
results of our online searches did not identify any com-
panies stating that they have developed TPPs for medical
tests, we would not expect to find such information on
company websites. Anecdotally, however, we have not
encountered any formal TPP development activity (by
this we mean definition of desirable test characteristics)
within the National Institute for Health Research Leeds
In Vitro Diagnostics Co-operative (NIHR Leeds) MIC
industry network.
As there are no guidelines on how TPPs for medical
tests should be developed, we did not formally assess
risk of bias. We did however appraise the transparency
with which the methodology underpinning each TPP
had been reported. Unfortunately, it was not possible to
fully evaluate the TPP developed by PATH [40] as the
online appendices were not accessible. Additionally, due
to poor methodological transparency, it was difficult to
assess with certainty authorship of TPPs and whether
authors of TPPs took part themselves in the consensus-
building meetings.
Future research
Although there is evidence of a common development
framework, this review highlights that there is consider-
able variability in the methods employed to draft TPPs
and inconsistencies in which test characteristics are de-
scribed. A key issue in reviewing the methods imple-
mented was the lack of transparency in methodology
reporting.
Guidance on best practice methods for developing
TPPs for medical tests would be highly beneficial. Simi-
larly to the US FDA guidance on TPPs for drugs, a guid-
ance document could be developed for TPPs for medical
tests summarising the purpose, attributes of TPPs and
which test characteristics should be included.
However, to inform the development of such guidance,
future research should focus firstly on how to systemat-
ically identify unmet clinical needs underpinning a cer-
tain disease area. Monaghan et al. [69] developed a
valuable checklist for identifying biomarkers based on
literature findings and consultations with experts. We
believe that this checklist could be pertinent for the
scoping phase underlying TPP development; however,
this would need further validation in this specific
context.
More research is also required to understand how to
better incorporate the assessment of desirable clinical
utility and cost-effectiveness of innovative tests into
TPPs. One possible way forward could be exploring how
and if care pathway analysis and early economic model-
ling could be integrated into the development of TPPs.
Care pathway analysis would provide clarity on the
mechanisms by which a test could impact on down-
stream patient outcomes. Early economic modelling
could be used to define desirable values for certain test
characteristics (e.g. test price, diagnostic sensitivity and
specificity) based on cost-effectiveness [67]. Therefore,
integrating care pathway analysis and early economic
modelling into TPP development might provide more
evidence-based information to the test developers.
Outside of the actual methodology for developing
TPPs, it would be useful to better understand whether
manufacturers develop tests strictly in line with TPPs, or
whether there are any factors which make this infeasible
or challenging. Additionally, we would be interested in
which methods manufacturers usually adopt to develop
TPPs to assess if there are any differences with the
methodological framework we highlighted here. To this
end, interviewing test manufacturers might provide in-
teresting insights on the intrinsic value of TPPs for the
industry.
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Most importantly to ensure that the development of
TPPs becomes widespread practice, it would be valuable
to explore how TPPs could be integrated into existing
regulatory paths for innovation such as the European
Union Regulation for In Vitro Diagnostics (Regulation
2017/746) and the US FDA Drug Development and Ap-
proval Process. It might then be possible to align test
characteristics featured in TPPs with evidence require-
ments which are relevant for market approval decisions
of new medical tests. This, in return, might increase the
applicability of TPPs for the industry.
Conclusions
Based on this review, we summarised current methodo-
logical practice into a framework of value to those inter-
ested in developing TPPs for medical tests.
We also identified some key weaknesses, including the
quality of the information sources underpinning TPPs
and failure to consider test characteristics relating to
clinical utility and cost-effectiveness.
This review thus provides some recommendations for
further methodological research on the development of
TPPs for medical test. This work will also help to inform
the development of a formal guideline on how to draft
TPPs for medical tests.
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